Hypothyroidism associated with nivolumab treatment of unresectable malignant melanoma.

Imafuku, K; Yoshino, K; Yamaguchi, K; Tsuboi, S; Ohara, K; Hata, H

Imafuku, K; Yoshino, K; Yamaguchi, K; Tsuboi, S; Ohara, K; Hata, H.

Affiliation

Imafuku K; Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
Yoshino K; Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
Yamaguchi K; Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
Tsuboi S; Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
Ohara K; Department of Dermatology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22 Honkomagoame, Bunkyo-ku, Tokyo, 113-8677, Tokyo, Japan.
Hata H; Department of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan.

Clin Exp Dermatol ; 42(2): 217-218, 2017 Mar.

Article in En | MEDLINE | ID: mdl-28052364

Subject(s)

Antibodies, Monoclonal/adverse effects; Antineoplastic Agents/adverse effects; Hypothyroidism/chemically induced; Melanoma/drug therapy; Rectal Neoplasms/drug therapy; Aged; Humans; Male; Nivolumab; Thyroid Hormones/blood

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Rectal Neoplasms / Hypothyroidism / Melanoma / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Risk_factors_studies Limits: Aged / Humans / Male Language: En Journal: Clin Exp Dermatol Year: 2017 Type: Article Affiliation country: Japan

Fulltext

XML

PubMed Links

Search on Google